YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The 2026 European Association for the Study of Diabetes ("EASD") annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster t…
Quick Read OZEM holds Lilly at 16% and Novo Nordisk at 13%, concentrating nearly 30% in GLP-1 leaders versus XLV's diluted multi-sector exposure. OZEM rounds out its GLP-1 core with Pfizer at 8% and Amgen at 4%, plus a 13% cash position th…
In a landmark move beginning July 1, 2026, Medicare, under its "GLP-1 Bridge" demonstration program, is set to provide eligible U.S. seniors with access to popular weight-loss medications like Wegovy, Zepbound, and Foundayo for a copay of…
[Injectable semaglutide pens for glucose control with a blue measuring tape on a clean background for weight loss and medical themes.] Eduardo Monroy Husillos/iStock via Getty Images Millions of Americans are set to gain access to certain…
Key Points Interested in Teladoc Health, Inc.? Here are five stocks we like better. With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are increasingly likely to benefit. Three potentially…
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since…
What happened According to a recent SEC filing dated May 13, 2026, Monashee Investment Management reduced its holding in Structure Therapeutics(NASDAQ:GPCR) by 175,000 shares during the first quarter. The estimated transaction value was $1…
Key Points Monashee sold 175,000 Structure Therapeutics shares; estimated trade size approximately $11.98 million based on the mean unadjusted close for the quarter. Quarter-end position value dropped by $13.24 million, reflecting both sal…
The weight loss drug market has evolved into one of the most explosive, flourishing segments of the global healthcare industry, driven by an unprecedented surge in demand for glucagon-like peptide-1 (GLP-1) receptor agonists. At the center…
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in the rapidly growing and fiercely competitive weight-loss market. Announced on March 19, 2026, the appr…
Shares of Danish drugmaker Novo Nordisk NVO suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from last year. This news also triggered a broa…
GLP-1 injection pen, pills and vial on desk with stock charts behind, signaling weight-loss drug boom. Key Points With the FDA approval of GLP-1 agonists in pill form, the healthcare industry is looking to build on last year's momentum. Gr…
The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. This pill, the first GLP-1 tablet specifica…
Wall Street was upbeat last week. The S&P 500 lost 0.6%, the Dow Jones advanced 1.1% and the Nasdaq retreated about 1.6% last week. The tech stocks were beaten down, taking a toll on the Nasdaq-100 as well as the S&P 500. Roundhill Magnifi…
Wall Street recorded a subdued November this year. The S&P 500 lost 0.04% over the past month (as of Nov. 28, 2025), the Dow Jones advanced 0.8%, and the Nasdaq Composite was off 0.9%. The ebbing chances of the Fed cutting rates in Decembe…
Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC. Shares touched around $1,059 on the day.…
Key Points You don't want to overpay for an exchange-traded fund (ETF). You don't want to get too aggressive with an ETF. You don't want to forget about diversification with ETFs. 10 stocks we like better than Vanguard S&P 500 ETF › If you…
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in…
Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs. The drugmaker also raised its fi…
Shares of Danish pharmaceutical giant Novo Nordisk A/S (NVO) tumbled 22% Tuesday after the company slashed its 2025 outlook and announced a CEO change, sending shockwaves through a range of ETFs tied to weight-loss drugs. Novo, best known…
Photo by Clay Banks via Unsplash GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment to help people manage their weight, several ex…